MLPA® is the gold standard for DNA copy number quantification and is used to study both hereditary disorders and tumours. MLPA can also be applied to investigate the methylation status of DNA sequences. MRC-Holland, the inventor and manufacturer of MLPA, offers 400 different MLPA panels. Popular applications include:
  • Predisposition to Cancer
  • Neuromuscular Disorders
  • Intellectual Disability
  • Solid Tumours

News

▷ New protocol versions available
As of 17 April 2018, new versions of the MLPA General Protocol and the MS-MLPA General Protocol have been published online. You can find the new versions on the MLPA Protocols page. Both protocols have been reorganized and rewritten. The most important changes can be found in the document history on page 2 of each protocol.

▷ MRC-Holland to Supply HhaI enzyme
Important news for MS-MLPA users: MRC-Holland has launched its own restriction enzyme SALSA HhaI. The HhaI enzyme – an essential component of MS-MLPA reactions – was developed to ensure that every aspect of MLPA, from start to result interpretation, is of the highest standards.

A free vial of SALSA HhaI enzyme (item number: SMR51) will be included with all orders containing an MS-MLPA probemix from 3 April until 30 September 2018. More information can be found here.

MLPA Workshops
MLPA workshop figure

To increase your understanding of MLPA, MRC-Holland continues to organize one-day MLPA workshops. During the theoretical and practical sessions, participants learn how to get the most out of their MLPA data from setting up the experiment to the result interpretation and troubleshooting.

Check out our destinations for 2018 on our Support Portal!

Subscribe to Our Newsletter
Subscribe here to our periodic newsletter to receive the latest information about our products, technology and website. You can unsubscribe anytime.
new products
P476-ZNRF3
Adrenocortical tumours and other solid tumours
improved products
P056-TP53
Li-Fraumeni syndrome (LFS) and tumour analysis
P175-Tumour Gain
Tumour Gain
P260-PALB2-RAD50-RAD51C-RAD51D
Hereditary predisposition to Cancer
P103-DPYD
Dihydropyrimidine dehydrogenase (DPYD) deficiency
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2018 MRC-Holland